Category Archives: Cell Therapy

USA TODAY

AJ Foyt planning to undergo stem cell therapy USA TODAY Foyt, 82, told IndyCar.com Saturday during a Verizon IndyCar Series test at Phoenix International Raceway that he plans to undergo stem cell therapy, likely in Cancun, Mexico, with injections into both ankles and shoulders as well as his blood. Foyt ... Local Physician Offers Latest in Stem Cell TherapyPR Leap (press release) New Nanofiber Stem Cell Therapy Developed By Kyoto UniversityUniversity Herald Stem Cell Therapy Market Is Expected to Reach USD 60.94 Billion by 2022Satellite PR News (press release) Digital Journal all 12 news articles »

See original here:
AJ Foyt planning to undergo stem cell therapy - USA TODAY

COLUMBUS For the past year, Dr. Todd Paczosa has been practicing what he calls the future of medicine.

The veterinarian treats his four-legged patients through stem cell therapy.

Im not anti-antibiotic, anti-medicine. I just believe that even in the future of cancer treatment that it is going to come down to your body healing itself, Paczosa said.

The process involves removing fatty tissue from a patient, extracting stem cells, then injecting the cells back into the animal's joints to promote healing.

Paczosa said he researched the treatment for about a decade before deciding to offer it at Redstone Veterinary Hospital in Columbus.

Our body is full of cells that heal. You get cut, your body heals. What we are doing is taking those cells, waking them up and saying, Hey, lets go to work, he said.

Since he started offering stem cell therapy last March, 17 dogs, horses and cattle have used the treatment. One of those patients is Butch, a 9-year-old schnauzer owned by Marge Biester of Columbus that was suffering from a strained ligament and achy joints.

He was really hurting. I had to do something for him, Biester said, adding that Butch wasnt putting much weight on his back leg when he walked.

The treatment was done in January. Butch was put under anesthesia to retrieve the fat tissue. Using equipment in-house, the stem cells were extracted and injected back into the dog that same day.

Paczosa, who has been a veterinarian for 23 years, said the entire process can be done in a day.

Biester noticed results in about two weeks.Butch wasnt doing his three-legged walk anymore and began acting like a more-active, younger version of himself.

Im amazed at how quickly he recovered, she said.

Paczosa said all of the animals he has treated so far have shown improvement.

One of these days, we will have one that doesnt work. Thats just medicine, but we havent had one yet, he said.

The possibility of the stem cell therapy not working can be a turnoff for some pet owners who might find it difficult to spend $1,900 to $2,400 for the treatment at Redstone. If it does work, Paczosa said the therapy is less expensive in the long run than putting an animal on medication for extended periods of time to ease the pain from arthritis.

Other pluses, he said, are that the regenerative therapy isnt as invasive as surgery and anti-rejection drugs don't have to be used since the cells come from the same animal.More than one joint can also be treated at a time and it can eliminate the use of non-steroidal anti-inflammatory drugs.

The biggest risks are putting the animal under anesthesia and infection of the surgical site where the fatty tissue is removed, typically from the shoulder area or abdomen.

Stem cell therapy is practiced at a few hundred veterinary clinics in the country. Redstone works with the animal stem cell company MediVet Biologics and uses that companys in-house technology.

Paczosa said owners have come from other states to use the therapy at his Columbus clinic.

Initial results from the procedure lasts about two years. An option to bank stem cells from a pet is available. A portion of what is taken can be stored in a lab and used again in the future.

For Paczosa's patients, results have been quick and ongoing.

Most owners have seen a dramatic improvement in two weeks. Our first patient is still seeing improvements, he said.

See the original post:
Stem cell therapy adds pep to pets - Columbus Telegram

A Phase 2 clinical trial assessing Mesoblast's (NASDAQ:MESO) allogeneic cell therapy candidate MPC-300-IV in patients with rheumatoid arthritis (RA) who have not responded to anti-Tumor Necrosis Factor (TNF) therapy [e.g., AbbVie's Humira (adalimumab)] showed a durable improvement in symptoms, physical function and disease activity with no safety signals observed.

The study enrolled 48 patients with active RA who were on a stable regimen of methotrexate and had an inadequate response to at least one anti-TNF agent. 63% (n=30/48) has received 1 - 2 biologic agents. Participants were randomized to receive a single infusion of 1MMesenchymal Precursor Cells(MPCs)/kg (n=16), 2M MPCs/kg (n=16) or placebo (n=16). The primary study period was 12 weeks and the total study duration was 52 weeks.

Both doses of MPC-300-IV outperformed placebo at both week 12 and week 39 as measured by ACR20/50/70 (ACR20 = 20% improvement in RA symptoms). The 2M-cell cohort showed the greatest response. At week 12, for example, 27% of the 2M-cell group achieved ACR70 compared to 0% for placebo. The proportion was 36% in the subgroup (n=11) who had received 1 - 2 biologics. The treatment effect was maintained through week 39.

The clinical development of MPC-300-IV is ongoing.

Read more:
Mesoblast's cell therapy candidate MPC-300-IV shows positive ... - Seeking Alpha

Takeda and TiGenix have presented 52-week data on their allogeneic expanded adipose-derived stem cells in Crohns disease patients with treatment-refractory complex perianal fistulas. The data show the Cx601 stem cells continue to outperform placebo one year after administration.

TiGenix presented the 24-week data from the successful phase 3 trial back in 2015, sparking a surge in its stock price and setting it up to land a deal with Takeda. Last year it followed up with the release of a first look at 52-week results confirming the efficacy outcomes seen in the earlier data drop.

Takeda and TiGenix have now shared another overview of the 52-week data at the 12th Congress of the European Crohns and Colitis Organisation (ECCO). The abstract includes treatment-related adverse event data that were absent from TiGenixs original release, but included in subsequent presentations.

Those 52-week data confirm the positive safety profile seen in the 24-week results. The rate of treatment-emergent adverse events was lower in the Cx601 cohort than the placebo plus standard of care arm at both time points. The same is true when only serious adverse events are analyzed.

The safety results complement the previously-released efficacy data. Among the 62% of patients who completed the 52-week follow-up, the results were comparable to those generated after 24 weeks. In the Cx601 arm, 56.3% of the modified intention-to-treat (mITT) population achieved combined remission after 52 weeks, compared to 51.5% after 24 weeks. The respective figures for the placebo cohort are 38.6% and 35.6%. The mITT population included all patients to undergo at least one post-baseline efficacy evaluation.

These data highlight that the efficacy and safety of a single administration of Cx601 were maintained during one year of follow up, TiGenix CMO. Marie Paule Richard said in a statement. It is important to also note that the definition of combined remission used in the ADMIRE-CD study, which includes both clinical and radiological assessment by MRI, is more stringent than the criteria commonly used in previous large scale, randomized clinical trials evaluating perianal fistulas in Crohns disease, based only on clinical assessment.

Relapse rates in the Cx601 group were rarer, too. Three-quarters of participants who responded to Cx601 after 24 weeks made it to 52 weeks without relapsing. The number falls to 55.9% among the placebo cohort.

TiGenix is hoping the data will prove compelling enough to secure a regulatory approval in Europe later this year. In parallel, TiGenix is setting up another phase 3 trial designed to deliver data to support approval in the U.S.. TiGenix expects the trial to start later this year.

Shares in TiGenix traded up 4% shortly after the stock exchange in Brussels opened for the day.

Visit link:
Takeda, TiGenix stem cell therapy shows sustained effect - FierceBiotech

TARPON SPRINGS, Fla. - Cosby just doesnt get around like he used to.

We have six dogs and hes always the one thats the last to get up. The last to get out, said his owner Brian Cirillo.

And for Cirillo, its sad to see.

I hate it. Its always like he always on his tippy topes on his back legs. So its heartbreaking.

But a new trial study that is about to start at the St. Francis Pet Care Center in Tarpon Springs, could be just what Cosby needs.

Veterinarian Mike Amsberry is offering stem cell therapy for dogs.

They are seeing that its very, very safe. And very effective.

This study is focused specifically on four-legged friends with arthritis.

But in the past hes seen stem cell treatments work wonders for other ailments.

Its cells treating the body, rather than then some foreign substance. Some medication.

In this trial, the stem cells come from umbilical cords of donor dogs.

Not only can qualified pets get the treatment for free, but owners are paid too.

Cosby seems like the perfect candidate.

I think thats where everything seems to be going with regard to medicine. So to be on the leading edge of that to potential help him without having to put him on a bunch of medicine is definitely a plus, said Cirillo.

The hope is one day Cosby will be able to keep up with the rest.

And lead the way to help thousands of other dogs.

For more information on the trial study go to petstemcells.org.

Excerpt from:
Local vet taking part in stem cell therapy study for dogs - WPTV.com

Capricor Therapeutics is dropping further development of its Phase II-stage heart failure drug Cenderitide and is terminating its license agreement with the Mayo Clinic for the natriuretic peptide receptor agonist program. "Our decision to return these rights is a strategic move as we prioritize our efforts to advance our core cell and exosome-based therapeutic development programs," said Linda Marbn, Ph.D., Capricor president and CEO.

Capricor said it expects to reach key clinical milestones with both the cell and exome therapy programs during 2017. Topline data from the Phase I/II HOPE clinical study with lead cell therapy candidate CAP-1002 (allogeneic cardiosphere-derived cells) is expected during Q2 2017. The trial is evaluating CAP-1002 in patients with Duchenne muscular dystrophy (DMD)-associated heart disease. The firm said it is separately planning a clinical trial, anticipated to start during 2017, to investigate whether CAP-1002 therapy can boost skeletal muscle function in men and boys with DMD.

We are also committing increased attention to our exosomes program, and we expect to file an IND application for CAP-2003 (cardiosphere-derived cell exosomes) in the second half of this year," added Dr. Marbn. Capricor is developing CAP-2003 for the potential treatment of ophthalmic disorders, including ophthalmic graft-versus-host disease (oGvHD).

CAP-1002 is an allogeneic cardiac cell therapy product manufactured from donor heart tissue. The treatment has been granted orphan drug designation by the FDA for the treatment of DMD. Capricor and partner Janssen Biotech are developing a commercial manufacturing process for CAP-1002 as part of their potentially $337.5 million collaboration, established in January 2014, to develop the cell therapy program for cardiovascular applications. In May of last year, Capricor received a $3.8 million grant from the California Institute for Regenerative Medicine to support the Phase I/II HOPE study.

CAP-2003 exosomes are obtained from CAP-1002 cardiosphere-derived cells (CDCs). The exosome technology is being developed under a 2014 license agreement with the Cedars-Sinai Medical Center. In October 2016, Capricor was granted up to $4.2 million from the NIH to evaluate CAP-2003 exosome therapy for treating hypoplastic left heart syndrome. The previous month the firm received a $2.4 million grant from the U.S. Department of Defense to establish a commercial manufacturing platform for CAP-2003.

The rest is here:
Capricorn Drops Cenderitide to Focus on Cell and Exosome Therapies - Genetic Engineering & Biotechnology News (press release)

Stem cell therapy treatment gives new lease of life to 5-year-old Jamshedpur February 17, 2017 , by Desk 83

Ranchi : Till very recently, it was believed that brain damage is irreversible. However, now with emerging research; we understand that it is possible to repair the damaged brain tissue using cell therapy.

Again, today there are still many people in India who have not preserved their stem cells through cord blood banks. For all those patients, who have lost their hopes in finding a new treatment for neurological related disorders, adult stem cell therapy offers a new hope for such kind of patients.

Dr Alok Sharma, Director, NeuroGen Brain and Spine Institute, Professor and Head of Neurosurgery, LTMG Hospital & LTM Medical College, Sion said Stem cell therapy is emerging as one of the newer treatment options for conditions like Autism, Cerebral Palsy, Mental retardation, Muscular Dytrophy, Spinal Cord Injury, Paralysis, Brain Stroke, Cerebellar Ataxia and Other Neurological Disorders. This treatment has the potential to repair the damaged neural tissue at molecular, structural and functional level.

Dr. NandiniGokulchandran, Deputy Director, Neurogen Brain and Spine Institute saidStem Cell Therapy (SCT) done at NeuroGen Brain and Spine Institute is a very simple and safe procedure. Stem Cells are taken from patients own bone marrow with the help of one needle and are injected back in their Spinal Fluid after processing.

Since they are taken from the patients own body there is no rejection, no side effects, hence making SCT a completely safe procedure.

Today, we are presenting a case study of Ranchi based 5 yrs old Master Dhairya Singh. He is a known case of brain damage due to lack of oxygen but not during birth. Dhairya was born in a normal manner, cried immediately after birth also his birth weight was appropriate.

There were no immediate post-natal complications reported. Dhariya was a normal child till the age of one and half years old. Then one day he suffered from an episode of pneumonia for which he was hospitalized for 6 days.

Last updated:Friday, February 17, 2017

Previous Article Rungta Mines launches computer literacy course

Next Article Jharkhand to see investment worth Rs 55K crore in highways in next 30 months: Gadkari

Read the original here:
Stem cell therapy treatment gives new lease of life to 5-year-old - Avenue Mail

A Phase 2 clinical trial assessing Mesoblast's (NASDAQ:MESO) allogeneic cell therapy candidate MPC-300-IV in patients with rheumatoid arthritis (RA) who have not responded to anti-Tumor Necrosis Factor (TNF) therapy [e.g., AbbVie's Humira (adalimumab)] showed a durable improvement in symptoms, physical function and disease activity with no safety signals observed.

The study enrolled 48 patients with active RA who were on a stable regimen of methotrexate and had an inadequate response to at least one anti-TNF agent. 63% (n=30/48) has received 1 - 2 biologic agents. Participants were randomized to receive a single infusion of 1MMesenchymal Precursor Cells(MPCs)/kg (n=16), 2M MPCs/kg (n=16) or placebo (n=16). The primary study period was 12 weeks and the total study duration was 52 weeks.

Both doses of MPC-300-IV outperformed placebo at both week 12 and week 39 as measured by ACR20/50/70 (ACR20 = 20% improvement in RA symptoms). The 2M-cell cohort showed the greatest response. At week 12, for example, 27% of the 2M-cell group achieved ACR70 compared to 0% for placebo. The proportion was 36% in the subgroup (n=11) who had received 1 - 2 biologics. The treatment effect was maintained through week 39.

The clinical development of MPC-300-IV is ongoing.

See more here:
Mesoblast's cell therapy candidate MPC-300-IV shows positive treatment effect in mid-stage study in treatment ... - Seeking Alpha

USA TODAY

A.J. Foyt planning to undergo stem cell therapy | USA TODAY Sports USA TODAY Auto racing legend A.J. Foyt is hoping to find the fountain of youth for a body that has taken quite a beating over the years. And like a handful of athletes before ... and more »

Read this article:
A.J. Foyt planning to undergo stem cell therapy | USA TODAY Sports - USA TODAY

Team owner A.J. Foyt watches his drivers during practice for the Indianapolis 500 on Monday, May 23, 2016, afternoon at the Indianapolis Motor Speedway.(Photo: Matt Kryger/IndyStar)Buy Photo

Racing legend A.J. Foyt is hoping to find the"fountain of youth."

The 82-year-old four-time winner of the Indianapolis 500 toldVerizon IndyCarmedia that he plans to undergo stem-cell therapy to help repair his ankles and shoulder. He also will have stem cells injected into hisblood.

Foyt's body has taken quite a beating over the years. According to the story, he suffered a broken back during a NASCAR race in 1964 and broken feet and legs during a 1991 IndyCar crash. In 2005, hewas stung more than 200 times by bees while trapped under his bulldozer at his Texas ranch. He's had knee and hip replacements, and in 2014 underwent triple-bypass heart surgery.

Foyt will undergo the therapy in Cancun, Mexico, as the treatment is not available in the United States.

It used to be you would have to go to Germany to get this procedure, but now it's available in Cancun and that is probably where I'll have it done, Foyt said Saturday during the Verizon IndyCar Series open test at Phoenix Raceway. I'm not in good health like I used to be and, if my son Larry hadn't taken over (running) the team four years ago, I would have had to shut it down. It's something he likes to do and I'm backing him 100 percent.

I feel better this year than I did last year, Foyt continued. If I get to feeling bad, I probably won't show up at the race. But I'm going to do that stem cell deal. My wife, Lucy, has been pretty sick lately. Dan Pastorini (the former NFL quarterback) did it and it helped him. Peyton Manning (the former Indianapolis Colts and Denver Broncos quarterback) did it for his neck and it really helped him. Tony Dorsett (the former Dallas Cowboys running back) did it, so I think we should try it.

Read the full story at indycar.com.

Autoplay

Show Thumbnails

Show Captions

Read the original:
AJ Foyt planning to undergo stem-cell therapy - Indianapolis Star